Barclays has initiated coverage on Envista Holdings Corp (NVST) with an Overweight rating, marking the firm's first assessment of the company. This decision reflects Barclays' analysis of Envista's business dynamics, industry positioning, and growth potential.
Headquartered in Brea, California, Envista Holdings engages in the manufacturing and marketing of dental products, diagnostics, and treatment solutions. The company boasts a diversified portfolio that addresses a range of clinical needs for dental professionals, with over 30 brands including Nobel Biocare, Ormco, DEXIS, and Kerr. As of December 8, 2025, Envista's stock is priced at $22.13, and the company has a market capitalization of $3.3 billion. Its trailing twelve months (TTM) price-to-earnings (P/E) ratio stands at 215.04, with an earnings per share (EPS) of $0.08.
Upcoming earnings reports are scheduled for April 29, 2026, and July 29, 2026, with EPS estimates of $0.28 and $0.30, respectively. Recent performance has shown positive surprises, including a Q3 2025 EPS of $0.32, exceeding estimates by 14.7%.
Analyst ratings such as this one provide a professional perspective based on extensive research and financial modeling. However, it is important for investors to consider a variety of factors, including company fundamentals and market trends, when making investment decisions. Analyst opinions can evolve as new information emerges, and differing views may exist among analysts regarding the same company.